Kimura E, Nikiforova M, Zhu Z, Knauf J, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003, 63,1454-1457.

Mitsutake N, Knauf JA, Mitsutake S, Mesa Jr C, Zhang L and Fagin JA. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation and chromosomal instability in thyroid PCCL3 cells. 2005. Cancer Research. 65(6):2465-73.

Ciampi R, Knauf JA, Kerler, R, Gandhi M, Zhu Z, Nikiforova M, Rabes H, Fagin JA, Nikiforov YE. Oncogenic AKAP9-BRAF fusion: a novel mechanism of MAP kinase pathway activation in radiation-induced and sporadic thyroid cancer. 2005. J Clin Invest. 115(1):94-101.

Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao X, Refetoff S, Nikiforov YE, Fagin JA. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Research. 2005. 65(10):4238-45.

Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa Jr. C, Knauf JA, Zhang L, Taira K, Fagin JA. BRAF mediates RET/PTC-induced MAPK activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology. 2006. 147 (2):1014-9.

Ouyang B, Knauf JA, Smith EK, Zhang L, Ramsey T, Yussuf N, Batt D, Fagin JA. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Research. 2006 12 (6):1785-93.

Mesa Jr C, Mitsutake N, Knauf JA, Sartor M, Medvedovic M, Tomlinson C, Mirza M, Weber G, Fagin JA. Conditional activation of the RET/PTC3 and B-RAFV600E oncoproteins in thyroid cells is associated with unique patterns of gene expression that predict distinct functional properties and a preferential role of BRAF in extracellular matrix remodeling. Cancer Research. 2006. Jul 1;66(13):6521-9.

Knauf JA, Ouyang B, Knudsen E, Fukasawa K, Babcock, Fagin JA. Oncogenic RAS induces accelerated transition through G2/M and defects in the G2 DNA damage and mitotic spindle checkpoints. J. Biol Chem. 2006. 281 (7): 3800-9

Akeno-Stuart N, Croyle M, Knauf JA, Malaguarnera R, Vitagliano D, Santoro M, Stephan C, Grosios K, Wartmann M, Cozens R, Caravatti G, Fabbro D, Lane HA, Fagin JA. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells: Implications for use of biomarkers in targeted cancer therapies. Cancer Res. 2007. 67(14):6956-64.

Croyle M, Akeno N, Knauf JA, Fabbro D, Lane H, Fagin JA. RET/PTC Induced Cell Growth Is Mediated In Part By Epidermal Growth Receptor Activation: Evidence For Molecular And Functional Interactions Between RET And EGFR. Cancer Res 2008. 68 (11):4183-91.

Chen X, Mitsutake N, LaPerle K, Akeno N, Zanzonico P, Longo V, Mitsutake S, Kimura E, Geiger H, Santos E, Wendel HG, Franco A, Knauf JA, Fagin JA. Endogenous Expression Of Hras G12V Induces Developmental Defects and Neoplasms With Copy Number Imbalances Of The Oncogene. Proc Natl Acad Sci USA, 2009 May 12;106(19):7979-84.

Knauf JA, Fagin JA. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr Opin Cell Biol 2009 Apr;21(2):296-303.

Ricarte Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Janakiraman N, Solit D, Knauf JA, Tuttle RM, Ghossein R, Fagin JA. Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA and AKT1. Cancer Res 2009 Jun 1;69(11):4885-93.

Franco AT, Malaguarnera R, Refetoff S, Liao XH, Lundsmith E, Kimura S, Pritchard C, Marais R, Davies TF, Weinstein LS, Chen M, Rosen N, Ghossein R, Knauf JA, Fagin JA. Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci U S A. 2011 Jan 10 108(4):1615-20.

Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA, Fagin JA. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene 2011. 14;30 (28):3153-62.

Chakravarty D, Santos E, Ryder M, Knauf J, Liao XH, West B, Bollag G, Kolesnick R, Thin T, Rosen N, Zanzonico P, Larson S, Refetoff S, Ghossein R, Fagin JA. Small-molecule MAPK inhibitors restore RAI incorporation in murine thyroid cancers with conditional oncogenic BRAF activation. J Clin Invest. In press.